PHOTOPORATION OF NK92 CELLS WITH BIODEGRADABLE POLYDOPAMINE NANOSENSITIZERS AS A PROMISING STRATEGY FOR THE GENERATION OF CAR-NK CELL THERAPIES.

被引：0

作者：

Hinnekens, C. ^{[1
]}

Harizaj, A. ^{[1
]}

Goemaere, I. ^{[1
]}

Berdecka, D. ^{[1
]}

De Smedt, S. ^{[1
]}

Vandekerckhove, B. ^{[2
]}

Fraire, J. ^{[1
]}

Braeckmans, K. ^{[1
]}

机构：

[1] UGent, Lab Gen Biochem Phys Pharm, Ghent, Belgium

[2] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium

来源：

HUMAN GENE THERAPY | 2022年 / 33卷 / 7-8期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

P060

引用

页码：A34 / A35

页数：2

共 50 条

[41] Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells Using Feeder Cell or Non-Feeder Cell Expansion Systems [J].

Liu, Dongfang .

MOLECULAR THERAPY, 2022, 30 (04) :349-349

[42] Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens [J].

Lima, Vitoria A. ;

Mitsugi, Thiago G. ;

Okamoto, Oswaldo K. .

CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)

[43] DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy [J].

Cifaldi, Loredana ;

Melaiu, Ombretta ;

Giovannoni, Roberto ;

Benvenuto, Monica ;

Focaccetti, Chiara ;

Nardozi, Daniela ;

Barillari, Giovanni ;

Bei, Roberto .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[44] UMBILICAL CORD BLOOD (UCB)-DERIVED NATURAL KILLER (NK) CELLS PROVIDE A HIGHLY SCALABLE SOURCE FOR GENE CIRCUIT ENGINEERED ALLOGENEIC CAR-NK THERAPIES [J].

Iyer, D. ;

Gorman, W. ;

Wood, T. ;

Blanco, C. ;

Lorente, M. ;

Nguyen, D. ;

Lee, B. ;

Kiedaisch, B. ;

Lee, P. .

CYTOTHERAPY, 2021, 23 (05) :S90-S91

[45] HSC and iPS cell-derived CAR-NK cells as reliable cell-based therapy solutions [J].

Arias, Jonathan ;

Yu, Jingwei ;

Varshney, Mukesh ;

Inzunza, Jose ;

Nalvarte, Ivan .

STEM CELLS TRANSLATIONAL MEDICINE, 2021, 10 (07) :987-995

[46] FAPα-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS [J].

Kuenzel, S. R. ;

Arriens, M. ;

Rackwitz, W. ;

Pappermann, J. ;

Thiel, J. ;

Kronstein-Wiedemann, R. ;

Eitler, J. ;

Tonn, T. .

CYTOTHERAPY, 2024, 26 (06) :S177-S177

[47] Development of Multi- Engineered iPSCDerived CAR-NK Cells for the Treatment of B-Cell Malignancies [J].

Borges, Luis ;

Wallet, Mark A. ;

Bullaughey, Chiamin-Liao ;

Naso, Michael F. ;

Gurung, Buddha ;

Keating, Shelby ;

Carton, Jill M. ;

Wheeler, John C. ;

Campion, Liam ;

Mendonca, Mark ;

Jessup, Heidi K. ;

Beqiri, Marilda ;

Chin, Diana ;

Quinn, Hillary Millar ;

Morse, Barry A. .

BLOOD, 2021, 138

[48] Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells [J].

Maddineni, Sainiteesh ;

Silberstein, John L. ;

Sunwoo, John B. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)

[49] CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies [J].

Romanski, Annette ;

Uherek, Christoph ;

Bug, Gesine ;

Seifried, Erhard ;

Klingemann, Hans ;

Wels, Winfried S. ;

Ottmann, Oliver G. ;

Tonn, Torsten .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (07) :1287-1294

[50] Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy [J].

Gierschek, Fenja ;

Schlueter, Juliane ;

Kuehnel, Ines ;

Feigl, Frederik Fabian ;

Schmiedel, Dominik ;

Pruefer, Maren ;

Buchinger, Leon ;

Cerwenka, Adelheid ;

Cappel, Claudia ;

Huenecke, Sabine ;

Koehl, Ulrike ;

Wels, Winfried S. ;

Ullrich, Evelyn .

TRANSFUSION MEDICINE AND HEMOTHERAPY, 2025, 52 (01) :42-60

← 1 2 3 4 5 →